Lifestyle Choices US Partner

RNS Number:5240F
Biofusion PLC
11 October 2007


For immediate release                                            11 October 2007



                                 BIOFUSION PLC
                         ("Biofusion" or "the Company")

                LIFESTYLE CHOICES SIGNS US LICENCE AGREEMENT
                             FOR PLAN AHEAD TEST

Biofusion plc (AIM: BFN), the university IP commercialisation company that turns
world class research into business, is today pleased to announce that Lifestyle
Choices Limited ("Lifestyle Choices"), Biofusion's female fertility spin-out
company, has signed a licence agreement with an undisclosed leading US
reproductive diagnostics company (the "Partner"), for the exclusive rights to
sell the Lifestyle Choices' Plan Ahead test, which helps measure a woman's
ovarian reserves, in North America and Canada.

Under the terms of the agreement, the Partner will be given exclusive rights to
market, sell and distribute Plan Ahead in North America and Canada through its
extensive network of specialty physicians. Lifestyles Choices will receive an
agreed fee, on a sliding scale, per test that is sold with a commitment by the
Partner to selling an agreed minimum number of tests per year.  The Partner
expects to launch the Plan Ahead test in the US before the end of 2007, upon
which time the Partner's name will be disclosed.

Plan Ahead is a patented triple hormone ovarian reserve test that helps a women
to make more informed decisions about conception.

Developed by Professor Bill Ledger, Professor of Obstetrics and Gynaecology at
the University of Sheffield, Plan Ahead measures three hormone levels in the
blood.  The first two are the ovarian hormones, Inhibin B and AMH; and the third
is FSH, a pituitary hormone.  The result is a predictive assessment of the
number of eggs in the woman's ovaries compared to the average range that would
be expected for women of the same age. The test is accurate for up to two years
ahead.

Commenting on the announcement, David Baynes, Chief Executive Officer of
Biofusion, said: "We are delighted to have signed an agreement with such a
leading US reproductive diagnostics company for our Plan Ahead test. They have
an excellent reputation in the US and we are very pleased to be working with
them.

"In an age where motherhood is often being postponed and the use of IVF is
becoming more common, Plan Ahead provides women with the ability to make a more
informed lifestyle choice about whether to try for a child sooner rather than
later. We are confident that there is a strong market for Plan Ahead in the US
and Canada and look forward to its success in these territories."

For further information about Biofusion please contact:

Biofusion                                                    [phone]
David Baynes / Stuart Gall

Buchanan Communications                                      [phone]
Lisa Baderoon / Mary-Jane Johnson / Catherine Breen

Nomura Code                                                  [phone]
Phil Walker / Clare Terlouw

About Biofusion

Biofusion was established in 2002 to commercialise university-generated IP.
Biofusion has signed long term agreements with two of the UK's top ten research
intensive universities (University of Sheffield and Cardiff University) giving a
combined R&D spend attributable to Biofusion of approximately #114 million a
year. The Company has a portfolio of 23 spin-out companies.

Biofusion's first agreement was a ten-year exclusive arrangement with the
University of Sheffield for the commercialisation of IP owned by the University
in the area of medical life sciences. Biofusion has shareholdings in a portfolio
of Sheffield University spin-out companies including Asterion, Axordia,
Biohydrogen, Diurnal and Phase Focus. The University of Sheffield was ranked 5th
in the UK for the quality of its life sciences research and will be spending an
estimated #0.5bn of research funding over the lifetime over the life of the
Sheffield Agreement.

In January 2007, Biofusion completed a long-term exclusive agreement with
Cardiff University, to commercialise 100% of all Cardiff University's
research-generated IP.  Biofusion has shareholdings in a portfolio of Cardiff
University spin-out companies including Abcellute, Q-Chip and Cardiff Protides.
Cardiff University was ranked 7th in the UK in the most recent research rankings
and will be spending over #1.0bn of research funding over the lifetime over the
life of the Cardiff Agreement.

About Lifestyle Choices

Lifestyle Choices launched its first product, a new triple hormone ovarian
reserve test called Plan Ahead, in 2006. The test, which is available from
www.boots.com, offers the most accurate hormone based ovarian reserve test
available to the public, enabling women to make more informed decisions about
when they try for a baby. Developed by Professor Bill Ledger, Professor of
Obstetrics and Gynaecology at the University of Sheffield, the Plan Ahead test
gives a predictive assessment of a woman's ovaries compared to the range that
would be expected for women of the same age. The company is developing its
second product aimed at the IVF market for launch in 2008.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCUASRRBRRRARA